[go: up one dir, main page]

WO2025166015A3 - Composés bifonctionnels de liaison à l'abl1 et leurs utilisations - Google Patents

Composés bifonctionnels de liaison à l'abl1 et leurs utilisations

Info

Publication number
WO2025166015A3
WO2025166015A3 PCT/US2025/013801 US2025013801W WO2025166015A3 WO 2025166015 A3 WO2025166015 A3 WO 2025166015A3 US 2025013801 W US2025013801 W US 2025013801W WO 2025166015 A3 WO2025166015 A3 WO 2025166015A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphorylation
compounds
abl1
substrate
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/013801
Other languages
English (en)
Other versions
WO2025166015A2 (fr
Inventor
Florence Fevrier WAGNER
Dominique Potin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photys Therapeutics Inc
Original Assignee
Photys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photys Therapeutics Inc filed Critical Photys Therapeutics Inc
Publication of WO2025166015A2 publication Critical patent/WO2025166015A2/fr
Publication of WO2025166015A3 publication Critical patent/WO2025166015A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés qui se lient à la protéine kinase-1 dépendante de la 3-phosphoinositide (ABL1) et/ou favorisent la phosphorylation ciblée d'un substrat. La phosphorylation induite du substrat cible peut modifier la structure et la fonction du substrat, ce qui permet de fournir des composés qui permettent la phosphorylation de substrats cibles, y compris ceux qui sinon ne peuvent pas constituer des substrats pour l'ABL1, et de fournir de nouveaux modes destinés à induire une phosphorylation stratégique. L'invention concerne également des composés qui constituent des intermédiaires des composés bifonctionnels. L'invention concerne également des composés qui se lient à un site allostérique d'ABL1 et inhibent la phosphorylation d'un substrat cible. L'invention concerne également des compositions pharmaceutiques comprenant les composés divulgués et des procédés de promotion de la phosphorylation de substrats cibles dans un échantillon biologique par l'administration d'un composé ou d'une composition de l'invention.
PCT/US2025/013801 2024-02-02 2025-01-30 Composés bifonctionnels de liaison à l'abl1 et leurs utilisations Pending WO2025166015A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463549396P 2024-02-02 2024-02-02
US63/549,396 2024-02-02

Publications (2)

Publication Number Publication Date
WO2025166015A2 WO2025166015A2 (fr) 2025-08-07
WO2025166015A3 true WO2025166015A3 (fr) 2025-09-12

Family

ID=94871415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/013801 Pending WO2025166015A2 (fr) 2024-02-02 2025-01-30 Composés bifonctionnels de liaison à l'abl1 et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2025166015A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496100A1 (fr) * 1980-12-16 1982-06-18 Wellcome Found Derives de la pyrazoline, leur preparation et medicaments contenant ces substances
EP0127371A2 (fr) * 1983-05-21 1984-12-05 FISONS plc 1,N-Diaryl-4,5-dihydro-1H-pyrazol-3-amines, compositions les contenant et leurs procédés de préparation
EP0178035A1 (fr) * 1984-05-12 1986-04-16 FISONS plc 1,N-Diarylpyrazol-3-amines anti-inflammatoires, compositions les contenant et leur préparation
WO1990014338A1 (fr) * 1989-05-20 1990-11-29 Fisons Plc Derives de 4-aminophenol a action anti-inflammatoire
WO2006122011A2 (fr) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Composes thiazole et procedes d'utilisation
US20240024490A1 (en) * 2021-04-09 2024-01-25 The Broad Institute, Inc. Bifunctional molecules for selective modification of target substrates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496100A1 (fr) * 1980-12-16 1982-06-18 Wellcome Found Derives de la pyrazoline, leur preparation et medicaments contenant ces substances
EP0127371A2 (fr) * 1983-05-21 1984-12-05 FISONS plc 1,N-Diaryl-4,5-dihydro-1H-pyrazol-3-amines, compositions les contenant et leurs procédés de préparation
EP0178035A1 (fr) * 1984-05-12 1986-04-16 FISONS plc 1,N-Diarylpyrazol-3-amines anti-inflammatoires, compositions les contenant et leur préparation
WO1990014338A1 (fr) * 1989-05-20 1990-11-29 Fisons Plc Derives de 4-aminophenol a action anti-inflammatoire
WO2006122011A2 (fr) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Composes thiazole et procedes d'utilisation
US20240024490A1 (en) * 2021-04-09 2024-01-25 The Broad Institute, Inc. Bifunctional molecules for selective modification of target substrates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIGOLAR ET AL: "Synthesis, structure and inhibitory effects on cyclooxygenase, lipoxygenase, thromboxane synthetase and platelet aggregation of 3-amino-4,5-dihydro-1H-pyrazole derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 24, 1 January 1989 (1989-01-01), pages 435 - 445, XP093278752 *

Also Published As

Publication number Publication date
WO2025166015A2 (fr) 2025-08-07

Similar Documents

Publication Publication Date Title
TWI663975B (zh) 治療肝臟疾病之方法
US9289415B2 (en) Treatment of cancer
ATE322264T1 (de) Medizinische zusammensetzungen als begleittherapie gegen krebs
US10905665B2 (en) Chemical modulators of signaling pathways and therapeutic use
Nguyen Targeting RSK: an overview of small molecule inhibitors
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
WO2002100845A8 (fr) Inhibiteurs de protease du hiv et compositions contenant ceux-ci, leurs applications pharmaceutiques, et matieres utiles a la synthese de ces inhibiteurs
A. Kulchitsky et al. Cytotoxic effects of chemotherapeutic drugs and heterocyclic compounds at application on the cells of primary culture of neuroepithelium tumors
Cunningham et al. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
AU784426C (en) Tissue factor antagonists and methods of use thereof
Huitema et al. The clinical pharmacology of alkylating agents in high-dose chemotherapy
Hernández-Reséndiz et al. Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade
WO2020170202A1 (fr) Inhibiteurs de kinases
EP1732569B1 (fr) Utilisation d'adefovir ou de tenofovir pour inhiber les virus semblables a mmtv impliques dans le cancer du sein et la cirrhose biliaire primaire
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
EP2210643A3 (fr) Combinaisons comprenants des épothilones et leurs utilisations pharmaceutiques
WO2025166015A3 (fr) Composés bifonctionnels de liaison à l'abl1 et leurs utilisations
Kostapanos et al. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
JP2008523138A (ja) Ｒｕｎｘ２をアセチル化してＲｕｎｘ２活性を増加させることによって、ＢＭＰによる骨形成経路を活性化させる方法
TW200306853A (en) Therapeutic agent for glomerular disease
MEP0408A (xx) Derivati hinociklicnog hinazolina kao inhibitori pde7
KR20160083806A (ko) 콜레스테롤 관련 질환의 예방 및 치료용 조성물
WO2025019599A3 (fr) Composés bifonctionnels de liaison à la kinase et leurs utilisations
UA84020C2 (ru) Ингибитор проникновения вируса вил

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25710163

Country of ref document: EP

Kind code of ref document: A2